Long-acting refillable nanofluidic implant (NanoMPI)- SC
For more information, contact: Alessandro Grattoni at agrattoni@houstonmethodist.org
Development Stage:
Preclinical – Early (Pre1)
Hormonal/Non-Hormonal:
Hormonal
Delivery Route & Method:
Topical - Implant (Subcutaneous)
Developer:
- University of Washington
- Methodist Hospital Research Institute (HMRI)
Funding:
- Nat. Institute Allergy & Infect. Diseases (NIAID)
Funding Mechanism:
NIAID R01
Active Ingredient(s):
- Etonogestrel
- Islatravir (EFdA)
- Lenacapavir
Product Indication(s):
- HIV
- Unintended Pregnancy